Spondyloarthritis & psoriatic arthritis
Retention rate of TNF inhibitors versus IL-17 inhibitors in ankylosing spondylitis patients with prior biologics experience
Authors' conclusion
In patients with AS who had prior experience with biologics, the drug retention of TNF inhibitors tended to be higher compared to IL-17 inhibitors in real-world clinical practice.
Study context
- Population
- Ankylosing spondylitis (AS) patients with prior biologics experience (inefficacy or adverse events with biologics), real clinical practicepropensity score matched
- Participants
- 148 patients
- Exposure
- TNF inhibitor vs IL-17 inhibitor as second- or higher-line biologic
- Outcome
- Drug retention (drug survival)
Methodological detailspropensity score matched, real-world clinical practice
- Propensity score matched
- Real-world clinical practice
Main finding
As reported in the abstract
Drug survival (Kaplan-Meier) · median follow-up 31.4 months
- IL-17i vs TNFi: P = 0.134
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Drug retention, discontinuations unrelated to treatment failure censoredLower retention of IL-17 inhibitors more pronounced | P = 0.034 |
| Drug retention, used for reasons other than psoriasis aggravation (subgroup)Lower retention of IL-17 inhibitors more pronounced | P = 0.028 |
Factors associated with drug discontinuation (multivariable Cox regression)
- Number of previous biologics, HR
- 1.62 (95% CI 1.17-2.23, P = 0.003)
- BASDAI, HR
- 1.3 (95% CI 1.03-1.65, P = 0.030)
- Class of biologics, HR (95% CI 0.96-4.63, P = 0.064); did not reach statistical significance
- 2.11
Original publication
Retention rate of TNF inhibitors versus IL-17 inhibitors in ankylosing spondylitis patients with prior biologics experience. Arthritis Res Ther. Published 4 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →